Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

View Amneal Pharmaceuticals, Inc. Class A AMRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Chirag K. Patel, Co-Founder and Co-CEO, highlighted "another consecutive quarter of strong performance and growth with revenues of $720 million and adjusted EBITDA of $184 million," and announced an ...

Amneal Pharmaceuticals AMRX has a diversified business model spanning generics, specialty drugs and government distribution.

On April 22, 2026 Amneal Pharmaceuticals, Inc. announced that it entered into an agreement to acquire Kashiv BioSciences, LLC. Under the terms of the agreement, Amneal will pay $375 million in cash ...

Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒ Adjusted EBITDA of $202 million; ...

Amneal is voluntarily recalling four lots of Vancomycin Hydrochloride for Oral Solution, 250 mg/5 mL packaged in 80 mL, 150 mL or 300 mL pack sizes, to the consumer level. Some bottles may have been ...

On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a year ago and missing the consensus of $0.15. The company reported sales of ...

Amneal Legal Department is among the finalists of The New Jersey Law Journal's 2025 In House of Impact the Year Award. Read a Q&A with them below. 2024 was another transformative year of development ...

Brookhaven-based Amneal Pharmaceuticals is looking to expand as the publicly traded company's revenue and profits have grown.

As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange Book, counsel for Teva and Amneal presented oral arguments in the Court of ...

Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.